Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs for treatment-induced myelosuppression in hematologic malignancies
NCT05672420Phase 2Unknown
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in myelosuppression. Primary endpoints: Dose-limiting toxicities up to 12 days, Adverse Events up to 21 days and 1 more. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT05672420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672420.